Castle Biosciences, Inc. Share Price & Technical Analysis
CSTL · $19.69 (-2.28%)
Healthcare / Diagnostics & Research
$19.69
-2.28%
Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), atopic dermatitis (AD), and uveal melanoma. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the likelihood of a positive sentinel lymph node and the risk of metastasis for…
Price chart
Seasonality
May has 2 positive and 2 negative years (last 5 years shown)
-20% return in May, -1% avg return in past 3 year May month.
-60% return in 2026, 42% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 1% | -25% | -15% | -2% | -20% | – | – | – | – | – | – | – | -60% |
| 25 | 6% | -21% | -8% | 0% | -21% | 28% | -25% | 58% | -5% | 12% | 57% | -2% | 79% |
| 24 | 9% | -22% | 18% | -5% | 10% | -8% | 12% | 24% | -4% | 22% | -14% | -12% | 30% |
| 23 | 14% | -8% | -10% | 0% | 7% | -44% | 24% | 18% | -16% | -7% | 29% | 9% | 17% |
| 22 | 2% | 0% | 5% | -51% | 0% | -3% | 28% | 5% | -9% | -4% | -9% | 0% | -35% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Downtrend · Weak
Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), atopic dermatitis (AD), and uveal melanoma. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the likelihood of a positive sentinel lymph node and the risk of metastasis for patients with invasive cutaneous melanoma; TissueCypher, a risk stratification spatialomics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, and low-grade dysplasia BE; AdvanceAD-Tx, a non-invasive GEP test which is designed to guide systemic treatment selection for patients aged 12 years and older with moderateto-severe AD; DecisionDx-SCC, a GEP test for cutaneous squamous cell carcinoma; and MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions. It also provides DecisionDx-UM, a risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma. The company offers its products to dermatology and gastroenterology markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$559.89M
P/E ratio
—
52W high
$44.28
52W low
$14.59
Volume
3,77,785
Beta
1.11
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Castle Biosciences, Inc. share price today?
- Castle Biosciences, Inc. (CSTL) last traded around $19.69 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does CSTL have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for CSTL. Download the app for real-time alerts.
- How can I analyze Castle Biosciences, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.